Details

Autor(en) / Beteiligte

• Merle, Corinne S
• Fielding, Katherine
• Sow, Omou Bah
• Gninafon, Martin
• Lo, Mame B
• Mthiyane, Thuli
• Odhiambo, Joseph
• Amukoye, Evans
• Bah, Boubacar
• Kassa, Ferdinand
• N'Diaye, Alimatou
• Rustomjee, Roxana
• de Jong, Bouke C
• Horton, John
• Perronne, Christian
• Sismanidis, Charalambos
• Lapujade, Olivier
• Olliaro, Piero L
• Lienhardt, Christian

Titel

A Four-Month Gatifloxacin-Containing Regimen for Treating Tuberculosis

Ist Teil von

• The New England journal of medicine, 2014-10, Vol.371 (17), p.1588-1598

Ort / Verlag

Waltham, MA: Massachusetts Medical Society

Erscheinungsjahr

2014

Quelle

MEDLINE

Beschreibungen/Notizen

• Shortening treatment regimens for tuberculosis may help control the disease. In this trial, patients with tuberculosis in sub-Saharan Africa received either a 4-month gatifloxacin-based regimen or the standard 6-month regimen. The gatifloxacin regimen was less effective. Shortened antituberculosis treatment regimens are expected to improve patient adherence to treatment, thus favoring better case management and disease control and minimizing the risk of drug resistance. 1 – 3 The first indication that fluoroquinolones had the potential to shorten tuberculosis treatment was from an observational study in India 4 in which ethambutol was replaced with ofloxacin. The fourth-generation fluoroquinolones gatifloxacin and moxifloxacin have shown mycobactericidal activity that is better than that of ofloxacin in vitro 5 and in vivo, 6 – 9 and these agents have the potential to shorten treatment. Gatifloxacin was chosen for this study on the basis of its bactericidal-activity profile, cost, . . .